Hamill John P. 4

What Happened
John P. Hamill, Senior Vice President and Chief Financial Officer of Aprea Therapeutics (APRE), participated in a private placement that closed January 30, 2026. He purchased 5,700 shares of common stock at $0.89 per share for a total of $5,073. In addition to the shares, he received 5,700 common warrants as part of the same private placement (the warrant portion is reported as a derivative acquisition).

Key Details

• Transaction date: January 30, 2026; filing date: February 2, 2026 (timely Form 4 filing).
• Purchase: 5,700 shares at $0.89/share — total cash paid $5,073. (Report code P = Purchase.)
• Derivative: 5,700 common warrants received (also reported with code P); price for the warrants is not separately listed in the Form 4.
• Shares owned after transaction: not specified in the filing.
• Footnotes: The purchase arose from a securities purchase agreement dated Jan 28, 2026, that closed Jan 30, 2026. Warrants are immediately exercisable but subject to ownership/voting caps (exercise cannot cause beneficial ownership >4.99% or voting power >9.99%). The warrants expire on or prior to the second anniversary of the earlier of (i) effectiveness of a registration statement for the underlying shares or (ii) the date the underlying shares become eligible for sale under Rule 144 (with the detailed exercise/expiration mechanics set forth in the footnotes).

Context

• This was a direct purchase in a private placement (coded P), not a sale. Purchases by insiders are often of interest to investors because they reflect the insider acquiring company stock, but filings are factual and do not state motivation.
• The derivative transaction reflects receipt of warrants accompanying the share purchase; they are not the same as an option exercise or a sale of shares.